Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers
Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of INO-4212 and Its Components, INO-4201 and INO-4202, Given With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers
Sponsor: Defense Advanced Research Projects Agency
Listed as NCT02464670, this PHASE1 trial focuses on Ebola Vaccine and remains completed. Sponsored by Defense Advanced Research Projects Agency, it has been updated 10 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jul 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Sep 2018 — Jul 2019 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE1
-
May 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Apr 2017 — May 2017 [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
-
Feb 2017 — Apr 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
May 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Defense Advanced Research Projects Agency
- GeneOne Life Science, Inc.
- Inovio Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .